linjc16/ctgov huggingface dataset:
Ultrasound for Detection of Prostate Cancer

Study Overview
=================
Brief Summary
-----------------
Clinical proof of concept of dual-frequency ultrasound imaging for detection and visualization of prostate cancer.

Detailed Description
-----------------
Prospectively recruited patients before prostatectomy and/or definitive radiotherapy will be included in the study. Dual-frequency ultrasound imaging will be compared to standard transrectal ultrasound and MRI. Imaging of primary tumor with dual-frequency ultrasound technology including the use of microbubble contrast-media. A prostate biopsy and blood sample will be taken from each patient, for histopathology and explorative biomarkers.

Official Title
-----------------
Dual-frequency Ultrasound for Detection of Prostate Cancer

Conditions
-----------------
Prostate Cancer

Intervention / Treatment
-----------------
* Device: SURF


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18 years onwards Signed written informed consent to perform rectal and transperineal ultrasound Exclusion Criteria: N/A

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Dual-frequency ultrasound<br>Dual-frequency ultrasound for detection of prostate cancer | Device: SURF<br>* Dual-frequency ultrasound<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical proof of concept of dual-frequency ultrasound imaging for detection and visualization of prostate cancer. | Sensitivity and specificity outcome measures | 1 day | 
| Clinical proof of concept of dual-frequency ultrasound imaging for detection and visualization of prostate cancer. | Comparing dual-frequency ultrasound, shear waves ultrasound, CEUS to MRI and histopathological findings | 1 day |
Spatiotemporal Dimensions of Metabolism in Autochthonous Tumors of GBM Patients

Study Overview
=================
Brief Summary
-----------------
To learn how altered metabolism in GBM causes tumor growth and resistance to drug therapy. In this pilot research study, we will dose GBM patients with a form of nicotinamide (a natural vitamin) that we can track. The nicotinamide will be converted to methyl nicotinamide (MeNAM) in the tumor. We will measure how fast the nicotinamide is converted to methyl nicotinamide. We believe that the speed of this chemical reaction in the tumor (fast versus slow) may be correlated with GBM aggressiveness

Official Title
-----------------
Spatiotemporal Dimensions of Metabolism in Autochthonous Tumors of GBM Patients

Conditions
-----------------
Glioblastoma Multiforme

Intervention / Treatment
-----------------
* Procedure: Surgical removal of the GBM tumor
* Other: d4-NAM infusion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Preoperative MRI consistent with a primary intracranial malignant brain tumor. Must be 18 years of age or older. Patient eligible for debulking surgery/resection. Exclusion Criteria: Inability to obtain pre-operative IV access. Use of Tru Niagen, Basis (or any other nicotinamide riboside (NR)-containing NAD+ booster) or niacin supplements within one month prior to Study Visit 1. Participation in studies involving investigational drug(s) within 30 days prior to Study Visit 1 Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 56 days prior to Study Visit 1 (participants may not donate blood any time during the study, through the final study day) Presence of any condition that, in the opinion of Dr. Field, compromises participant safety or data integrity or the participant's ability to complete study days. Pregnancy, lactation or < 9 months postpartum from the Study Visit 1 date.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Participants in surgery<br>Surgical removal of the GBM tumor. | Procedure: Surgical removal of the GBM tumor<br>* Surgical removal of the GBM tumor<br>Other: d4-NAM infusion<br>* Following the surgical removal of the GBM tumor, GBM patients will be dosed with a form of nicotinamide (a natural vitamin) that we can track. The nicotinamide will be converted to methyl nicotinamide (MeNAM) in the tumor. We will measure how fast the nicotinamide is converted to methyl nicotinamide. We believe that the speed of this chemical reaction in the tumor (fast versus slow) may be correlated with GBM aggressiveness.<br>* Other names: Nicotinamide;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Subtyping of GBM tumors as Classical, Proneural or MES (based on RNA-seq) | Resected tumor tissue will undergo routine testing | 2 months |
Impact of the CRRT Management Protocol on Prognostic Outcome in Patients With Septic Acute Kidney Injury

Study Overview
=================
Brief Summary
-----------------
The implementation of CRRT nursing team management program in the treatment of SAKI can significantly reduce the incidence of adverse events and complications in CRRT nursing, which has a positive role in improving the success rate of CRRT treatment and the clinical outcome of patients.

Official Title
-----------------
Xinjiang Medical University of Affiliated Tumour Hospital

Conditions
-----------------
To Explore the Influence of CRRT Nursing Team Management Plan on the Prognosis of SAKI Patients

Intervention / Treatment
-----------------
* Other: Implement the CRRT specialist nursing group management program on the basis of routine care


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The Guidelines for Emergency Treatment of Sepsis / Septic Shock in China (2018)[4]Diagnostic criteria for moderate sepsis; ② meets the Organization for Improving Global Kidney Disease Outcomes (KDIGO) Clinical Practice Guidelines: AKI[5]Relevant diagnostic criteria in; ③ received CRRT as indicated for CRRT; ④ in ICU for longer than 24 hours; ⑤ signed consent. Exclusion Criteria: with chronic organ failure, or advanced malignancy; ② with previous history of chronic kidney disease, retrorenal urinary tract obstruction; ③ with incomplete clinical data.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Control group<br> | |
| Observation group<br> | Other: Implement the CRRT specialist nursing group management program on the basis of routine care<br>* Training the department nurses on CRRT related theoretical knowledge and operation skills; guiding the process of CRRT different treatment modes, solving CRRT nursing problems, evidence-based nursing guidance; consulting CRRT treatment and nursing related treatment, timely understanding the new progress; responsible for CRRT nursing quality control, etc.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To explore the influence of CRRT nursing team management plan on the prognosis of SAKI patients. | The incidence of unplanned removal of CRRT, unplanned extubation and CRRT nursing related complications in the observation group were lower than those in the control group (P <0.05). Kaplan Meier survival curve showed that the survival rate of patients in the observation group was higher than that in the control group (P <0.05). | 3-10 days |
Prevalence of Sexually Transmitted Infections (STIs) and Coinfections in the General Population

Study Overview
=================
Brief Summary
-----------------
Prevalence of Sexually Transmitted Infections (STIs) and co-infections in the general population

Official Title
-----------------
Prevalence of Sexually Transmitted Infections (STIs) and Co-infections in the General Population

Conditions
-----------------
HIV Infections

Intervention / Treatment
-----------------
* Diagnostic Test: Blood sample


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subject, male or female, 18 years of age or older Subject capable of understanding the purpose of the research having given their free and informed written consent Subject presenting to the laboratory for a biological examination Affiliated subject or beneficiary of a social security scheme Exclusion Criteria: - Protected subject: adult under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Adults<br> | Diagnostic Test: Blood sample<br>* Blood sample<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The prevalence of each STI will be assessed by the participant's positive or negative status for each pathogen, determined by the following screening tests: | HIV testing is based on finding antibodies to HIV-1 and HIV-2 and P24 antigen of the virus; Hepatitis B screening is based on HBsAg (hepatitis B surface antigen) research; Herpes screening is based on testing for antibodies to Herpes Simplex virus (HSV-1 and HSV-2); Papilloma virus screening is based on the HPV-HR test from a smear on the cervix; Chlamydia screening is based on a nucleic acid amplification (NAAT) test; Gonorrhea screening is based on the identification of the bacteria on a urine sample or secretions from the vagina or cervix; Screening for trichomoniasis is based on a molecular diagnosis that involves identifying the parasite's DNA from a genital or urinary sample; The detection of syphilis is based on antibody research. | 3 years |
Assessment of vGRF Measurement During Walking With Feetme® Insoles in Healthy Adults

Study Overview
=================
Brief Summary
-----------------
The objective of the present study is to demonstrate the validity and reliability of vGRF and other gait parameters measurement in healthy adults while walking with FeetMe® insoles compared to force plates (AMTI BP400600) and video motion capture system (Vicon NEXUS and MX-T40) .

Official Title
-----------------
Assessment of Vertical Ground Reaction Force Measurement During Walking With Feetme® Insoles in Healthy Adults

Conditions
-----------------
Healthy Volunteers

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria. Volunteers with following criteria satisfied: Between the ages of 18 and 80. Shoe size between 35 to 46. Body weight from 40kg to 120kg. Able to walk for 30 mins without assistance. Comfortable with using a smartphone. Non-inclusion Criteria. A volunteer will not be included if one of the following conditions is met: cognitive or behavioral problems limiting communication or participation in the study deprivation of liberty by a legal or administrative decision adults subject to a legal protection measure or unable to express their consent pregnant, parturient and nursing mothers people admitted to a health or social establishment for purposes other than research Past or planned surgery with the possibility of impacting walking in the past 3 months or which had an impact on walking: orthopedic surgery, trauma to the lower limbs and spine, urological or gynecological surgery, brain and spinal cord surgery . Chronic disease affecting walking: Rheumatological, orthopedic, painful, neurological pathology.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Single-Groupe<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| precision of measurement of 'maximum weight acceptance' and 'push-off' peaks in healthy adults by FeetMe® insoles | The primary objective of this clinical trial is to quantify precision of measurement of two peaks of vGRF, peaks that correspond to 'maximum weight acceptance' and 'push-off', also called 'heelmax load' and 'toemax load' for healthy adults by FeetMe® insoles compared with Vicon and force plates during a free walk test. | between February 2022 and November 2022 |
Evaluation of Two Varnishes on the Improvement of White Spot Lesions in Children

Study Overview
=================
Brief Summary
-----------------
A randomized control trial evaluating the effect of the Giomer varnish versus fluoride varnish on the color improvement of the white spot lesion in permanent anterior teeth of children aged between 8-14 years by using a spectrophotometer at baseline, after 3 months and after 6 months

Official Title
-----------------
Evaluation of Giomer Varnish Versus Fluoride Varnish on The Color Improvement of White Spot Lesions in Permanent Teeth of Children: A Randomized Controlled Clinical Trial

Conditions
-----------------
White Spot Lesion

Intervention / Treatment
-----------------
* Drug: giomer varnish


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: • Patients with good general health. Adequate oral hygiene, Patients who didn't receive remineralizing agents during the last 3 months other than regular toothpaste. Exclusion Criteria: Uncooperative child. Active carious lesion. Labial surface restoration.

Ages Eligible for Study
-----------------
Minimum Age: 8 Years
Maximum Age: 14 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: giomer varnish<br>Giomer varnish containing surface pre-reacted glass-ionomer (PRG) filler, will be administrated once. | Drug: giomer varnish<br>* Giomer varnish containing surface pre-reacted glass-ionomer (PRG) filler, will be administrated once.<br>|
| Active Comparator: fluoride varnish<br>5% NaF fluoride varnish, it will be administrated once. | Drug: giomer varnish<br>* Giomer varnish containing surface pre-reacted glass-ionomer (PRG) filler, will be administrated once.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| white spot lesion color change | assessment of white spot lesion color by using spectrophotometer | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient response to the treatment | Patient response to the treatment using facial image scale, scores from 1 to 5 | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
white spot lesion, fluoride varnish, Giomer Varnish
Dynamic Monitoring of ctDNA Predicts Recurrence of Advanced Ovarian Cancer After Primary Treatments

Study Overview
=================
Brief Summary
-----------------
Patients who receive satisfactory PDS, currently the change in CA125 during chemotherapy can only be used to evaluate the effectiveness of chemotherapy. This study plans to use ctDNA dynamic monitoring to detect minimal residual lesions during treatment, to demonstrate the application value of ctDNA dynamic monitoring in predicting the recurrence of ovarian cancer after PDS/IDS surgery.

Detailed Description
-----------------
This study plans to include ovarian cancer patients who have undergone PDS/IDS surgery. By analyzing the surgical tissue samples of ovarian cancer patients, we aim to identify risk factors related to the prognosis and recurrence of ovarian cancer. By monitoring the ctDNA status after PDS surgery, we analyze the role of ctDNA-MRD in predicting postoperative recurrence of ovarian cancer. By monitoring the MRD status at the end of the 3rd cycle of adjuvant chemotherapy and at the end of adjuvant treatment, we analyze the predictive role of serial cDNA-MRD for the efficacy of adjuvant treatment, providing a basis for determining the number of cycles of adjuvant treatment after PDS.

Official Title
-----------------
Dynamic Monitoring of ctDNA Predicts Recurrence of Advanced Ovarian Cancer After Primary Treatments

Conditions
-----------------
Ovarian Cancer Stage IV, Ovarian Cancer Stage III

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ≥ 18 years old. Patients diagnosed with stage IIIC-IVA ovarian cancer through pathological examination. The participant has read and fully understands the patient information, and has signed the informed consent form. The patient is willing to undergo primary debulking surgery (PDS) or interval debulking surgery（IDS）. - Exclusion Criteria: Other tumors have been detected within the last 5 years. Organ transplant recipients or those who previously had non-autologous (allogeneic) bone marrow or stem cell transplants. Patients was deemed unsuitable to participate in this study by other researchers. Patients who have previously received neoadjuvant chemotherapy or targeted therapy.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 2 years DFS rate | The recurrence rate of patients at two years after surgery | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| DFS | Disease-free survival | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ctDNA, Ovarian cancer, PDS, IDS, adjuvant chemotherapy
Study of the in Vivo Expression of MU Opioid Receptors Using PET and the Selective Tracer [C-11] Carfentanil in Normal Weight and Obese Subjects

Study Overview
=================
Brief Summary
-----------------
Positron emission tomography (PET) is a nuclear medicine technique that allows the measurement, in vivo in humans, with a non-invasive method, of the regional distribution of substances marked with positron emission isotopes such as C-11, in different districts bodily. Using this method it is therefore possible to directly measure at the level of the brain the distribution of receptors, enzymes, reuptake sites, as well as their interaction with various classes of drugs and the related modifications that may be present during the pathology. The evaluation of the endogenous opiate receptor system will be implemented by comparing the in vivo binding maps of 11C carfentanil in the two groups of subjects under examination (normal weight, NOR and obese, OB, based on body mass index, BMI); in fact, experimental data deriving from previous studies support the hypothesis that the basis of obesity and incorrect eating behaviors is a dysregulation of the endogenous ligand-mu opioid receptor interaction. The comparison of the data deriving from the analysis of the PET exams performed on the two groups of subjects will therefore allow us to evaluate the alterations of the opioid system possibly present in obese subjects.

Official Title
-----------------
Study of the in Vivo Expression of MU Opioid Receptors Using PET and the Selective Tracer [C-11] Carfentanil in Normal Weight and Obese Subjects

Conditions
-----------------
Nuclear Medicine

Intervention / Treatment
-----------------
* Diagnostic Test: PET for the analysis of mu opioid receptor expression.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: aged between 20 and 40 years; structured sports activity < 2 hours per week Exclusion Criteria: drug allergy; clinical evidence of neuropsychiatric pathologies.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Male

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: PET for the analysis of mu opioid receptor expression.|PET for the analysis of the expression of mu opioid receptors and to directly measure the distribution of the receptors and enzyme reuptake sites at the brain level.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PET with 11C CARFENTANIL for the analysis of the expression of mu opioid receptors. | Study of the expression of mu opioid receptors in normal weight and obese subjects | 3 years |